In this episode, Dr Rachel Giles dives into:
- Brodalumab real-world evidence in psoriasis - Von Kiedrowski et al.
- Delgocitinib for hand eczema - Worm et al.
- JAK1 inhibition successful in hidradenitis suppurativa - Alavi et al.
- Secukinumab in kids with severe chronic plaque psoriasis - Bodemer et al
- Omalizumab discontinuation in urticaria due to COVID-19 - Gulcan et al.
Posted on
Previous Article
« First randomised T2T trial using endoscopy to guide dose escalation Next Article
Risk factors for severe COVID-19 among IBD patients »
« First randomised T2T trial using endoscopy to guide dose escalation Next Article
Risk factors for severe COVID-19 among IBD patients »
Table of Contents: EADV 2020
Featured articles
Late-Breaking News
Selective IL-23 blocker shows potential in psoriasis treatment
Promising results with nanobody treatment in psoriasis
Light at the end of the tunnel for chronic hand eczema
Epidermolysis bullosa: Novel wound treatment on the horizon
Efficacious non-steroidal topical for psoriasis
Oral JAK 1 inhibitor leads to fast itch relieve and remarkable skin clearance in AD
COVID-19: What Dermatologists Need to Know
Biologic psoriasis treatment and COVID-19 risk: Contradictory results
Much to be learned about COVID-19 and the skin
JAK Inhibitors – A Fascinating Novel Drug Class
JAK inhibitors in AA: re-establishing the immune privilege of hair follicles
JAK1 inhibition successful in hidradenitis suppurativa
Topical JAK inhibition: a novel treatment option for patients with mild-to-moderate AD
Urticaria – What’s new
Chronic inducible urticaria can require some detective work
Chronic spontaneous urticaria: hives, wheals & biomarkers
Ligelizumab for chronic spontaneous urticaria: a new star on the horizon
Infectious Diseases: Novel Developments
Bacterial resistance in skin infections – a challenging threat
Borreliosis: A multifaceted disease
Scabies – A global health challenge
Upcoming Treatments
Meaningful sleep improvement with IL-13 inhibition
Preventing foot odour with zinc oxide coated socks
Baricitinib in AD: Efficacy paired with consistent long-term results
Best of the Posters
Real-world data on brodalumab affirms efficacy and fast onset of action
Heightened risk for psychiatric comorbidities in hidradenitis suppurativa patients
Effects IL-13 blocker improves with longer treatment duration
Related Articles
December 17, 2020
Real-world data on brodalumab affirms efficacy and fast onset of action
December 17, 2020
Risky sexual behaviour and STIs on the rise despite the pandemic

December 18, 2020
Letter from the Editor
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com